VCEL
HealthcareVericel Corporation
$37.08
+$1.47 (+4.13%)
Jan 5, 2026
Price History (1Y)
Analysis
Vericel Corporation is a biotechnology company operating in the healthcare sector. With a market capitalization of $1.88B and revenue of $258.72M (TTM), the company has a significant scale. Vericel employs 357 individuals. The company's financial health indicates moderate profitability, with gross margin, operating margin, and profit margin standing at 73.8%, 5.1%, and 5.1% respectively. Returns on equity and assets are 4.5% and 1.1% respectively. The balance sheet shows a debt-to-equity ratio of 30.66 and a current ratio of 4.87, indicating manageable levels of debt and sufficient liquidity. The valuation context suggests that Vericel is priced at a premium, with a price-to-earnings (TTM) ratio of 142.62 and forward P/E of 63.93. The company has experienced revenue growth of 16.6% year-over-year, but earnings growth data is not available. Dividend information is not provided.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $1.88B
- P/E Ratio
- 142.62
- 52-Week High
- $63.00
- 52-Week Low
- $29.24
- Avg Volume
- 619.94K
- Beta
- 1.18
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 357